Hint mode is switched on Switch off
For swift navigation between sections

Logicbio Therapeutics
LEI 549300GHIQDMXT6NPC14

PDF download

Choose all Reset all
Download Cancel
Organization name
Logicbio Therapeutics, Inc.
Country name
USA
Country of registration
USA
Industry
Pharmaceutical Preparation and Biotechnology
Public debt
-

Upgrade to Premium features

Cbonds consolidates global bond, stock, ETF and indices data into a single platform — so you can analyze faster, make informed investment decisions and outperform the market

Get access
Welcome to Cbonds

  • Full access to the largest bond database

    Bond parameters,
    prospectuses

  • Seamless
    Data export

    Analyze the data in the most efficient way

  • Bond pricing

    Current & historical quotes from 400+ stock exchanges & OTC market

  • Smart risk assessment

    Credit ratings, financial reports

Get access

Latest data on

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Quotes

Request sent
Access denied
Send request
Quotes provided by information providers are indicative in nature

Profile

LogicBio Therapeutics, Inc., a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient’s genome to provide a therapeutic effect. LogicBio Therapeutics, Inc. was founded in 2014 and is based in Cambridge, Massachusetts.

Awards

News

16/11/2022 Logicbio Therapeutics: Termination Of A Material Definitive Agreement, Completion Of Acquisition Or Disposition Of Assets, Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard Transfer Of Listing, Material Modification To Rights Of Security Holders, Changes In Control Of Registrant, Departure Of Directors Or Certain Officers; Election Of Directors; Appointment Of Certain Officers; Compensatory Arrangements Of Certain Officers, Amendments To Articles Of Incorporation Or Bylaws; Change In Fiscal Year, Financial Statements And Exhibits
14/11/2022 Logicbio Therapeutics: Results Of Operations And Financial Condition, Results Of Operations And Financial Condition
14/10/2022 Logicbio Therapeutics: Other Events
03/10/2022 Logicbio Therapeutics: Entry Into A Material Definitive Agreement
03/10/2022 Logicbio Therapeutics: Entry Into A Material Definitive Agreement, Regulation Fd Disclosure, Other Events, Financial Statements And Exhibits
All organization news

Documentation

IFRS/US GAAP reports

2022
I q eng
II q eng
III q eng
2021
I q eng
II q eng
III q eng
IV q eng
2020
I q eng
II q eng
III q eng
IV q eng
2019
I q eng
II q eng
III q eng
IV q eng
2018
III q eng
IV q eng
Show all Hide
Authorization required
You need to request access

Stocks

Public debt by currencies

Show more Hide

Codes

  • LEI
    549300GHIQDMXT6NPC14
  • SIC
    2836 BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
  • CIK
    0001664106
Registration is required to get access.